21 May 2009
Pancreatic islets allotransplantations – indications and patients’ qualification
M Wszoła, A Kwiatkowski, K Pawelec, A Berman, P Fiedor, M Durlik, L Pączek, A ChmuraAnn Transplant 2009; 14(1): 46-46 :: ID: 880366
Abstract
Background: Diabetes and its complications are the growing problems in nowadays World. The new era of diabetes treatment was started when Banting and Best have discovered and isolated insulin from a dog's pancreas. Another break-through appeared after first successful pancreas transplantation. Unfortunately this type of treatment leads to many postoperative complications. Alternative treatment for patients with diabetes is pancreatic islets transplantations. In 2008 the first islets transplantation in Poland was done. It is still a matter of discussion the proper qualification and indications for this procedure. The aim of the study was to asses indications for islets transplantation.
Material/Methods: Between June and December 2008 one hundred twelve
patients with diabetes type I were observed in our outpatients clinic - 45 after kidney transplantation or unsuccessful pancreas/kidney transplantation and 67 without diabetic nephropathy. In the first round of qualifications the BMI, episodes of hypoglycemia, daily insulin intake and presence of diabetic complications were measured and observed. The group of 27 patients was hospitalized in order to perform more detailed assessments. The USG Doppler of portal vein and iliac arteries, gastroscopy, viral status assessments, metabolic assessments (peptide - C, HBA1C), biochemistry and morphology of blood and urine, ophthalmologic, dentist, cardiologic assessments were performed.
Results: Nine persons were disqualified from further study due to: chronic hepatitis B and C (4 prs), emotional instability (3 prs), type 2 -diabetes (2 prs). 18 persons had undergone qualifications for pancreatic islets transplantations: 9 patients with diabetic nephropathy (6 after Kidney transplantations and 3 under permanent dialysis treatment), 9 with unstable diabetes without nephropathy. Six of all were also qualified to pancreas transplantations. All patients were C-peptide negative. Mean age was 40.4±12 years, mean time of diabetes treatment was- 17±9 years, mean BMI was - 22.3±3 kg/m2, mean daily insulin intake was - 39±13 IU, mean clearance of creatinine was - 93±50 ml/min, mean level of HBA1C was - 7.99±2.33 mg%.
Conclusions: Patients with type-I diabetes with low daily insulin intake, low BMI, good creatinine clearance and metabolic instability might be qualified for pancreatic islets transplantations.
Keywords: pancreatic islets
In Press
Original article
Diagnostic Utility of FAR1 Methylation Levels in Hepatocellular Carcinoma Patients Undergoing Liver Transpl...Ann Transplant In Press; DOI: 10.12659/AOT.951568
Original article
Inferior Long-Term Outcome of Fatty Liver Allografts After Orthotopic Liver TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.950589
Database Analysis
Identification and Validation of Liver Transplantation-Induced Acute Lung Injury Biomarkers Using a Bioinfo...Ann Transplant In Press; DOI: 10.12659/AOT.950289
Original article
Survival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellula...Ann Transplant In Press; DOI: 10.12659/AOT.950997
Most Viewed Current Articles
24 Aug 2021 : Review article 18,372
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
05 Apr 2022 : Original article 14,731
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 14,244
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
29 Dec 2021 : Original article 13,752
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588






